The mechanisms through which circulating GLP-1 activate the HPA axis remain to be elucidated, and may provide further evidence for the beneficial effect of GLP-1 receptor agonists in obesity and type 2 diabetes (T2DM) treatment. Here, GCG is linked to type 2 diabetes mellitus.